Skip to main content

Table 1 The background of the four patients with recurrent malignant glioma (RMG)

From: Boron neutron capture therapy with bevacizumab may prolong the survival of recurrent malignant glioma patients: four cases

Case No.

Age

Sex

Hist.

RPA class

Irradiated dose (Gy-Eq)

BV cycles

PsPD or RN

Survival (Months from BNCT)

     

Brain (Max)

Tumor (Max)

Tumor (Mini)

(Months from BNCT)

  

1

43

M

AA

3

11.4

118

36.1

3 (11 M)

RN

23 M, alive

2

41

M

GBM

4

12.1

88.5

36.6

4 (14 M)

RN

26 M, alive

3

60

M

AA

3

10.8

110

82.3

6 (4 M)

PsPD

16.5 M

4

34

F

AOA

3

11.5

71.6

30.1

6 (2 M)

PsPD

14 M

  1. Hist, histology; RPA, recursive portioning analysis; BV, Bevacizumab; PsPD, pseudoprogression; RN, radiation necrosis; BNCT, boron neutron capture therapy.